Strong results of the Phase 2a study for SER150 in Diabetic Nephropathy was announced:
- Serodus is planning to publish the details of the findings from the study later in 2017
- Results are currently being presented to potential partners, investors and scientific advisors
- Serodus is preparing for a pre-IND meeting
Serodus was delisted from Oslo Stock Exchange and is now a private company.
The company completed the subscription of a convertible loan of 25 MNOK Serodus is currently focussing all resources on SER150 for the treatment of patients with diabetic nephropathy.